Chaves, Yane Costa
Genaro, Karina
Crippa, José Alexandre
da Cunha, Joice Maria
Zanoveli, Janaína Menezes
Funding for this research was provided by:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (408517/2016-6)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (466805/2014-4)
Article History
Received: 3 August 2020
Accepted: 29 December 2020
First Online: 19 January 2021
Compliance with ethical standards
:
: JAC is co-inventor (Mechoulam R, JC, Guimaraes FS, AZ, JH, Breuer A) of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023” Def. US no. Reg. 62,193,296; 29/07/2015; INPI on 19/08/2015 (BR1120150164927). The University of São Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil) to “develop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.” JAC has received travel support from and was medical advisor of SCBD Centre. JAC has received a grant from University Global Partnership Network (UGPN) – “Global priorities in cannabinoid research excellence.” JAC is member of the international advisory board of The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), funded by the National Health and Medical Research Council through the Centre of Research Excellence).
: All experiments were conducted in accordance with the rules and legislation contained by the UFPR Animal Research Ethics Committee (CEUA number #1106).